Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20666000 | 0.78 | BRD4 (0.41) | MAPTLMNA | |
| SCHEMBL9252720 | 0.77 | MAPT (0.46) | MAPTPOLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL18857646 | 0.74 | MAPT (0.44) | MAPTPOLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL26496334 | 0.73 | MAPT (0.32) | MAPTLMNA | |
| SCHEMBL18999555 | 0.72 | MAPT (0.41) | MAPTPOLBLMNASMN1; SMN2 | |
| SCHEMBL3751829 | 0.71 | MAPT (0.57) | MAPTPOLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL19262494 | 0.71 | MAPT (0.57) | MAPTPOLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL26075213 | 0.71 | MAPT (0.57) | MAPTPOLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL24252607 | 0.69 | MAPT (0.60) | MAPTPOLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL12264670 | 0.69 | MAPT (0.55) | MAPTPOLBLMNASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | BACE1, STS, APP | MAPT 53/4885POLB 3116/4885LMNA 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.